Streetbeat News

Products Services

AMZN

DOX

Amdocs (NASDAQ:DOX) has announced a collaboration with Integrated Private Wireless on Amazon Web Services (AWS). This positions Amdocs as a key player in the Integrated Private Wireless on AWS program, enabling advancements in private network innovation. AWS customers can now access Amdocs Mobile Private Network (MPN) services via the AWS Marketplace. The collaboration will also empower the AWS sales force with Amdocs MPN expertise. One of the first customer applications from this collaboration is with Smartlite, a company that provides next-generation experiences on 5G networks.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 10:13 pm

BKTI

BK Technologies Corporation (NYSE:BKTI) has received a $315,000 purchase order from the U.S. Department of Defense for its BKR 9000 multiband radio. The order is part of the DoD's efforts to expand its existing fleet of radios. The BKR 9000 was selected after a competitive bid process due to its interoperability with existing P25 trunking infrastructure and its LTE-capable portable radio feature.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 10:12 pm

LCID

STLA

TSLA

Tesla's North American Charging Standard (NACS) is becoming the dominant charging standard in the electric vehicle (EV) world, with Lucid Group being the latest to adopt it. However, Volkswagen and Stellantis have yet to adopt the NACS. Stellantis has little incentive to do so as it is barely producing any EVs in the U.S., while Volkswagen owns the Electrify America charging network, which competes with Tesla's NACS Supercharger network.

Portfolio Pulse from Benzinga EV Insights

November 07, 2023 | 10:08 pm

LUMO

Lumos Pharma, Inc. (NASDAQ:LUMO) announced that its Phase 2 OraGrowtH210 and OraGrowtH212 trials of LUM-201 in pediatric growth hormone deficiency (PGHD) met all primary and secondary endpoints. The trials demonstrated that LUM-201 can enhance annualized height velocities (AHVs) in line with established standards for moderate PGHD patients undergoing recombinant growth hormone (rhGH) therapy. The company plans to discuss these data and finalize plans for a Phase 3 pivotal trial with the FDA in the first half of 2024.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 10:05 pm

LCID

Lucid Group's CEO, Peter Rawlinson, has announced a cut in the company's production forecast to align production with deliveries, clarifying that the company does not have a production problem.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 10:01 pm

DOX

NVDA

Amdocs (DOX) and NVIDIA (NVDA) have partnered to accelerate the adoption of generative AI in the $1.7 trillion telecom industry. The collaboration will leverage NVIDIA's DGX Cloud and Amdocs' amAIz LLMs to help service providers save costs and streamline operations.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 9:49 pm

NTDOY

Nintendo ADR (OTC:NTDOY) reported strong financial results for the first six months ending Sept. 30, with a 21.2% YoY increase in sales ($5.3 billion) and a 27% YoY increase in profit ($1.9 billion). The company also raised its profit forecast for the current financial year to approximately $2.8 billion. Despite the anticipation of Nintendo's next-generation console, the original Nintendo Switch saw increased sales, with 6.84 million units sold during the six-month period.

Portfolio Pulse from Franca Quarneti

November 07, 2023 | 9:39 pm

AAPL

BTCUSD

Unicoin, a publicly traded cryptocurrency, offers investors opportunities in real estate, pre-IPO companies, and a show similar to Shark Tank. The company is asset-backed, pays dividends, and is subject to auditing. Unicoin introduced real estate investing last fall and has a subsidiary show, 'Unicorn Hunters', where investors can take part in stakes in pre-IPO companies. The company plans for an ICO in the future. Apple Inc co-founder Steve Wozniak, a judge on 'Unicorn Hunters', is also an investor in Unicoin.

Portfolio Pulse from Chris Katje

November 07, 2023 | 9:33 pm

BBIO

Citi has initiated coverage on BridgeBio Pharma Inc (BBIO) with an optimistic outlook, citing the substantial market potential of acoramidis, especially after its recent Phase 3 successes in treating ATTR cardiomyopathy. Citi recommends a Buy/High Risk with a price target of $42. The analysts also anticipate that acoramidis could achieve blockbuster sales levels post its expected launch in H2 2024. Other promising candidates in BBIO's pipeline include infigratinib, encaleret, and BBP-418.

Portfolio Pulse from Vandana Singh

November 07, 2023 | 9:28 pm

RIVN

Rivian Automotive has increased its 2023 production guidance to 54,000 total units, citing progress on production lines, ramp of in-house motor line, and a positive supply chain outlook.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 9:10 pm